Breast Cancer

Docetaxel was associated with lower rates of peripheral neuropathy compared with paclitaxel for Black patients with breast cancer.

A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide patients through these effects.

Here’s a roundup of FDA approvals in the oncology space from October 2024.

While pregnancy-associated cancer risks increased with age, breast cancer during pregnancy tended to not impact obstetric risk.

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or metastatic breast cancer

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

Oncology nurses play a crucial role in monitoring the severity and frequency of treatment-related symptoms, particularly nausea.

Testing for ESR1 mutations is essential after ER-positive HER2-negative breast cancer progressed.

The DetermalO identified patients with early-stage triple-negative breast cancer who would benefit from presurgical atezolizumab plus carboplatin and nab-paclitaxel.

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer.

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained.

A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

Neoadjuvant immune checkpoint inhibitors plus chemotherapy also improved efficacy outcomes in PD-L1-positive/ERBB2-negative tumors.

Guiding treatment via response predictive subtype could be beneficial for identifying patients with high-risk breast cancer who may respond to Dato-DXd plus durvalumab.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.

Trastuzumab deruxtecan improved time to deterioration for pain and other categories, in patients with HER2 low/ultralow breast cancer.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine therapy.

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence.

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab.

DESTINY-Breast12 results showed that T-DXd led to overall and intracranial activity in patients with HER2-positive metastatic breast cancer.

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug in patients with ERBB2-positive breast cancer.

A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes.

Compared with available literature, the rates of medication-related osteonecrosis of the jaw were higher in patients with breast cancer and bone metastases treated with antiresorptive therapy.